Efficacy of moisturizer and acquisition of basic dermatological data in skin adverse event of epidermal growth factor receptor inhibitors.

Efficacy of moisturizer and acquisition of basic dermatological data in skin adverse event of epidermal growth factor receptor inhibitors. - Moisturizer and basic dermatological data in skin adverse event of EGFR inhibitors.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006360

Enrollment

Registered

2011-09-20

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Application of &quot

Hirudoid ointment&quot

or &quot

Hirudoid lotion&quot

No application

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Lung cancer patient to be administrated gefitinib or elrotinib. 2.Person who obtained document and agreement by own free will on full understanding after enough explanation when participating about examination is received. 3.over 20 years old.

Exclusion criteria

Exclusion criteria: 1.Person with skin disorder with wide body surface area. 2.Person with allergy to this moisturizer. 3.Person with severe bleeding tendency. 4.person who is judged as improper as included by the doctors.

Design outcomes

Primary

Measure	Time frame
Acquisition of basic dermatological data of the patients taking EGFR inhibitors.	—

Secondary

Measure	Time frame
The efficacy and safety of moisturizer for skin adverse events of EGFR inhibitors.	—

Countries

Japan

Contacts

Public ContactYoichi Moroi

Kyushu University Hospital Department of Dermatology

092-642-5585

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026